вторник, 26 июля 2016 г.

Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals in Zika Virus

Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals in Zika Virus


Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced today it has received funding to expand testing of our broad spectrum innate immune antivirals in Zika virus. Supplemental funding for Zika testing is being provided by the National Institute of Allergy and Infectious Disease to evaluate lead broad spectrum antivirals in preclinical models of Zika virus infection.



from Biotech News